Enter inventor name

Serge Mignani

This inventor holds 70 USPTO granted patents and 6 published patent applications and 3 EPO patents, primarily in Medicinal Chemistry (CPC class A61K). Top assignees: Aventis Pharma S.a., Rhone-Poulenc Rorer S.a., Rhone-Poulenc Sante. Active years: 1990-2026.

USPTO Granted Patents = 70 (Patent Applications = 6)

% Patents Active = 58.6

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 5.4

ph-index = 13

Forward Citations = 400(Granted Patents)

Forward Citations (Not Self Cited) = 384(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Livry, FR (1990 - 1991)
Livry-Gargan, FR (1991 - 1992)
Paris, FR (1994)
Ch.ang.tenay-Malabry, FR (1998)
Chätenay Malabry, FR (2001)
Chatenay Malabry, FR (1995 - 2024)

Company Filing History:

Rhone-Poulenc Rorer S.a.

Sanofi-A Ventis Deutschland Gmbh

Years Active: 1990-2026

Loading Chart...

Areas of Expertise:

Neoglycoconjugates

Heterocycles

Quinolyl Derivatives

Medicinal Products

Pharmaceutical Compositions

Pyrazolyl Derivatives

Thiazoline Derivatives

Inducible NO-Synthase

Azetidine Derivatives

Isoindolone Derivatives

Guanidinocarbonyl Compounds

Polyhydroxyalkylpyrazine

70 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12691069 - Synthetic glycolipids and glycoliposome compositions : suitable for cargo delivery to the central nervous system (2026-07-28),

2. 11925680 - Neoglycoconjugates as vaccines and therapeutic tools (2024-03-12),

3. 10973910 - Neoglycoconjugates as vaccines and therapeutic tools (2021-04-13),

4. 8163768 - 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them (2012-04-24),

5. 8048893 - Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them (2011-11-01),

6. 7638521 - 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them (2009-12-29),

7. 7589117 - Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them (2009-09-15),

8. 7531663 - 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them (2009-05-12),

9. 7524838 - Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them (2009-04-28),

10. 7232834 - Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor (2007-06-19),

11. 7232833 - 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them (2007-06-19),

12. 7230007 - Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom (2007-06-12),

13. 7227022 - Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase (2007-06-05),

14. 7078428 - Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them (2006-07-18),

15. 7078414 - Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them (2006-07-18),

Title: Innovations in Glycoconjugate Therapeutics: A Spotlight on Serge Mignani

Introduction

Serge Mignani, a prominent inventor and researcher based in Chatenay-Malabry, France, has made significant contributions to the field of glycoconjugate therapeutics. With an impressive portfolio of 69 patents, Mignani's work has propelled advancements in vaccine development and diagnostic tools. His latest inventions focus on neoglycoconjugates, showcasing both innovation and therapeutic potential.

Latest Patents

Mignani’s latest patents explore the use of neoglycoconjugates as vaccines and therapeutic tools. These neoglycoconjugates are synthesized by attaching a carbohydrate antigen intermediate to a free amine group of a carrier material, such as a carrier protein. The intermediate includes a linker that binds to the carbohydrate antigen via a thio ether bond, while the other end contains a functional group reactable with an amine group. The result is a covalently bound carbohydrate antigen to the carrier material through various bond types, including amide and carbamate bonds. Mignani’s patents highlight the applications of these neoglycoconjugates as antigens, immunogens, and diagnostic tools, emphasizing their potential in combating cancers, viral infections like SARS-CoV-2, and diseases linked to abnormal glycosylation.

Career Highlights

Throughout his illustrious career, Serge Mignani has been affiliated with prestigious companies such as Aventis Pharma and Rhône-Poulenc Rorer. His work in these innovative environments has allowed him to further his research and develop transformative therapeutic tools that have the potential to change the landscape of medicine.

Collaborations

Mignani has collaborated with numerous talented professionals, contributing to a collective advancement in the field. Notable coworkers include Jean-Christophe Carry and Patrick Jimonet, with whom he has shared insights and expertise to enhance the development of glycoconjugate technologies.

Conclusion

Serge Mignani stands out as an influential figure in the realm of glycoconjugate therapeutics. His 69 patents and ongoing research into neoglycoconjugates underline his dedication to innovation in vaccine and therapeutic development. As the landscape of medicine continues to evolve, Mignani's contributions will undoubtedly play a crucial role in shaping future advancements.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]